2
siRNAs from Dharmacon were deprotected and annealed according to the manufacturer's instructions. Four Ku70-siRNAs were used in an equimolar ratio as previously described (5) . Cyclin D1-siRNAs sequences were as follows: Cyclin D1 #1: 5'-ACACCAAUCUCCUCAACGAUU-3' (sense #1); 5'-UCGUUGAGGAGAUUGGUGUUU-3' (antisense #1); Cyclin D1 #2: 5'-GCAUGUUCGUGGCCUCUAAUU-3' (sense #2); 5'-UUAGAGGCCACGAACAUGCUU-3' (antisense #2); Cyclin D1 #3: 5'-GCCGAGAAGUUGUGCAUCUUU-3' (sense #3); 5'-AGAUGCACAACUUCUCGGCUU-3' (antisense #3); Cyclin D1 #4: 5'-GCACUUUCUUUCCAGAGUCUU-3' (sense #4); 5'-GACUCUGGAAAGAAAGUGCUU-3' (antisense #4). Unless otherwise mentioned, cyclin D1-siRNAs were used as a cocktail of #1-4 in an equimolar ratio.
Cyclin D2-siRNA sequences were 5'-GAACUGGUAGUGUUGGGUAUU-3' (sense) and 5'-UACCCAACACUACCAGUUCUU-3' (antisense). Cyclin D3-siRNA sequences were 5'-CUAGAACAAUCCAUGCUAUUU-3' (sense) and 5'-AUAGCAUGGAUUGUUCUAGUU-3' (antisense).
siRNA entrapment in nanoparticles.
siRNAs were mixed with full-length recombinant protamine (Abnova, Taipei City, Taiwan) in a 1:5 (siRNA:protein) molar ratio, in DEPC-treated water (Ambion Inc., Austin, TX) and were pre-incubated for 30 min at RT to form a complex (5) . For entrapment, lyophilized nanoparticles (i.e., β 7 I-tsNP, IgG-sNP, or sNP; 1~2.5 mg lipids) were rehydrated by adding 0.2 ml DEPC-treated water containing protamine-condensed siRNAs (1,000~3,500 pmol). The entrapment procedure was performed immediately before use. Concentrations of siRNAs and percent entrapment were determined by a Quant-iT™ RiboGreen™ RNA assay (Molecular Probes, Invitrogen) as described (6) .
In vitro transfection of siRNAs using β 7 I-tsNP.
Splenocytes or TK-1 cells that had been pre-cultured overnight at 37°C, 5% CO 2 in 24-well microtiter plates (2.5 x 10 5 cells in 200 µl media/well) were given aliquots (50 µl/well) of β 7 I-tsNP entrapping siRNAs or appropriate controls in the presence or absence of stimulation with immobilized CD3/CD28 mAbs (20 µg/ml each) or 2.5 ng/ml PMA plus 1 µg/ml ionomycin. Cells were cultured for 6 to 72 h at 37°C, 5% CO 2 and subjected to flow cytometry and/or real time RT-PCR analyses. In some experiments, TK-1 cells, pretreated for 12 h with 2.5 µg/ml aphidicolin to arrest cell cycle, were treated for another 12 h with β 7 I-tsNP entrapping siRNAs or appropriate controls in the presence of 2.5 µg/ml aphidicolin and in the presence or absence of PMA/ionomycin.
Serum and RNase stability.
Naked Ku70-siRNAs or Ku70-siRNAs entrapped in β 7 I-tsNP were incubated with 50% FCS or RNase A (20 ng/mL) for the indicated duration (0, 30, 60, and 120 min). Treated naked siRNAs were transfected into TK-1 cells using Amaxa TM nucleofection according to the manufacture's instructions. Treated β 7 I-tsNP-entrapped Ku70-siRNAs were transfected into TK-1 cells as described above.
Cell proliferation.
3 H-thymidine (1 µCi) was added for 16 h to treated lymphoid cells (5 x 10 4 ) in microtiter wells. Cells were harvested and analyzed by scintillation counting using a Top Count microplate reader (Packard).
Interferon assay.
Splenocytes (1 x 10 6 cells/ml) were mock treated or treated for 48 hrs with β 7 ItsNP entrapping 1,000 pmol luciferase-siRNA or 5 µg/ml poly (I:C). Expression of IFN or interferon responsive genes was examined by quantitative RT-PCR.
Cell adhesion assay.
Cell adhesion to integrin ligands immobilized in a V-bottom-well plate was studied as previously described (7) . Cells (7.5 x 10 4 cells per well) were treated with 1 µg/ml antibodies or nanoparticles.
Quantitative RT-PCR.
Quantitative RT-PCR using a Biorad iCycler was carried out as previously described (8) . Primers for mouse GAPDH, STAT1, OAS1, and IFN-β were used as previously described (8) . The following primer pairs were used:
Cyclin D1: 5'-GAATGTACCAGGAGCCATATC-3' (forward); 5'-CTCAGTACTACGAGTAATCCA-3' (reverse). mRNA expression levels of each transcript were normalized to that of GAPDH as previously described (8) .
Cell isolation and flow cytometry.
Mononuclear cells were isolated from the spleen and gut as previously described (9) . Flow cytometry of cell surface antigens was performed as previously described (5) . For intracellular staining of cyclin D1 and Ku70, cells were fixed and permeabilized with the Fix-and-Perm Kit TM (Caltag Laboratories, Burlingame, CA), stained with 1 µg/ml rabbit anti-mouse cyclin D1 (Santa Cruz Biotechnology, Santa Cruz, CA) on ice for 30 min, and counter-stained with FITC-conjugated goat anti-rabbit IgG (Zymed). Detection of Ku70 expression was conducted as previously described (5).
Image acquisition and processing.
Confocal imaging was performed using a Biorad Radiance 2000 Laser-scanning confocal system (Hercules, CA) incorporating with an Olympus BX50BWI microscope fitted with an Olympus 100X LUMPlanFL 1.0 water-dipping objective. Image acquisition was performed using Laserscan 2000 software and image processing was performed with Openlab 3.1.5 software (Improvision, Lexington, MA).
Mice and colitis model.
Wild-type and β 7 integrin knockout mice with a C57BL/6 background were obtained from Charles River Laboratories and maintained in a specific pathogen-free animal facility at Harvard Medical School. All animal experiments were approved by the Institutional Review Board of the Immune Disease Institute/CBR Institute for Biomedical Research. Colitis was induced in mice with dextran sodium sulphate (DSS) as previously described (9) . Briefly, C57BL/6 (Charles River Laboratories) mice were fed for 9 days with 3.5% (wt/vol) DSS (MP Biomedicals, Inc.) in drinking water. Suspensions (200 µl) of nanoparticles entrapping siRNAs were sonicated in a bath sonicator (Branson 3510) for 5 min, and immediately i.v. injected via tail veins. Body weight and clinical symptoms were monitored daily. Mice were sacrificed on day 9 and the entire colon was removed from cecum to anus, with colon length measured as a marker of inflammation. Distal colon cross-sections were stained with haematoxylin and eosin for histologic examination. Quantitative histopathologic grading of colitis severity was assessed as previously described (10) . Blood samples were obtained by cardiac puncture. Hematocrit was measured by HEMAVET TM 850 autoanalyzer (Drew Scientific Inc., Dallas, TX).
Bio-distribution studies and pharmacokinetic analysis.
Radiolabeled β 7 I-tsNP and IgG sNP were prepared by incorporating the nonexchangeable lipid label 3 H-cholesterylhexadecylether ( 3 H-CHE, 5 µCi/mg lipid) as previously described (3) . Suspensions (200 µl) of nanoparticles were sonicated in a bath sonicator (Branson 3510) for 5 min, and immediately i.v. injected via tail vein to 8-weekold female C57BL/6 mice (Charles River Laboratories) with or without DSS-induced colitis. Blood was sampled from the retro-orbital vein at 1, 6, and 12 h. Plasma was isolated from whole blood by centrifugation at 3000 x g for 5 min. Tissue homogenates 10% (w/v) were prepared in water using a Polytron homogenizer (Brinkman Instruments, Mississauga, Ontario, Canada). Aliquots (200 µl) of tissue homogenate or plasma samples were mixed with 500 µl Solvable TM (Perkin Elmer), and then incubated for 2 h at 60°C and for 1 h at room temperature for digestion. Digested samples (~700 µl aliquot) were mixed with 50 µl of 200 mM EDTA and 200 µl of hydrogen peroxide [30% (v/v)], incubated overnight for bleaching, and, following addition of 100 µl of 1 N HCl and 5 ml Ultima Gold, subjected to 3 H scintillation counting with a Beckman LS 6500 liquid scintillation counter. Blood correction factors were applied as previously described (3).
Statistical analysis.
In vitro data were analyzed using Student's t-test. Differences between treatment groups were evaluated by one-way ANOVA with significance determined by Bonferroniadjusted t-tests. We used the generalized estimating equations (GEE) approach to model disease scores collected over time and to compare disease severity of control versus treated groups (11) . Log fluorescence Cell number
Figure S1
Peer et al. Binding to β 7 integrins on splenocytes Peer et al. Figure S2 . The presence of hyaluronan is critical to maintaining the ability of nanoparticles to bind β 7 integrin during a cycle of lyophilization and rehydration. Nano-sized liposomes were surface-modified with either Alexa488-labeled antibodies alone (left panels) or with hyaluronan (HA) and Alexa488-labeled antibodies (right panels). Binding to the β 7 integrin on splenocytes was examined using flow cytometry both before (dashed lines) and after (solid lines) samples had been subjected to a cycle of lyophilization and rehydration. Particles surfacemodified with Alexa488-labeled control IgG serve as a negative control to reveal background binding (bottom panels). Note: after lyophilization/rehydration, liposomes surface-modified with hyaluronan and FIB504 mAb (topright panel; i.e., β 7 I-tsNP) retained the ability to bind splenocytes, whereas liposomes with FIB504 mAb alone lost this ability (top-left panel). To study whether hyaluronan, a CD44 ligand, could effectively deliver siRNA to silence in CD44 high -activated splenocytes, CyD1-siRNAs entrapped in hyaluronan-nanoparticles lacking β 7 integrin mAb (sNP-entrapping CyD1-siRNA) were tested. sNP entrapping 1,000 pmol CyD1-siRNA induced little silencing in CD44 high -activated splenocytes, supporting the idea that β 7 integrin mAb is necessary for intracellular siRNA delivery, a prerequisite for inducing effective gene silencing. (A & B) To demonstrate that an entrapment, and not merely a surface-association, of siRNA to β 7 I-tsNP is required for robust silencing, CyD1-siRNA surface-associated with β 7 ItsNP was studied. CyD1-siRNA surface-associated with β 7 I-tsNP (β 7 I-tsNP associated with CyD1-siRNA) was made by mixing a protamine-condensed CyD1-siRNA solution to fully water-rehydrated β 7 I-tsNP. CyD1-siRNA entrapped in β 7 I-tsNP (β 7 I-tsNP entrapping CyD1-siRNA) was made by rehydrating lyophilized β 7 I-tsNP with a protaminecondensed CyD1-siRNA-containing solution. Note that β 7 I-tsNP entrapping CyD1-siRNA exhibited ~100 times as potent silencing as did β 7 I-tsNP associated with CyD1-siRNA. Figure S5 . Entrapment in β 7 I-tsNP protects siRNAs from inactivation by serum (A) and RNases (B). Because degradation of siRNAs by RNases present in serum has the potential to greatly undermine their activity during in vivo delivery (13, 14) , the stability of siRNA entrapped in β 7 I-tsNP during exposure to RNase was examined. In contrast to naked Ku70-siRNA (1,000 pmol), which was inactivated following exposure to RNase A (20 ng/mL) or 50% serum, β 7 I-tsNP-entrapped Ku70-siRNA (1,000 pmol) maintained its ability to silence a specific gene, demonstrating the protective properties of entrapment in β 7 I-tsNP against RNase degradation. Ku70-siRNA entrapped in β 7 I-tsNP was delivered to TK-1 cells as described in Methods. Naked Ku70-siRNA was delivered to TK-1 cells using an Amaxa TM nucleofection. Activities of Ku70-siRNA were studied by examining the efficacy of Ku70-knockdown 48 h after delivery. Note that β 7 I-tsNP and Amaxa showed comparable Figure S11 . Blockade of β 7 integrin-MAdCAM-1 interaction by β 7 I-tsNP. Because the β 7 antibody FIB504 used for generating β 7 I-tsNP was previously characterized as a function-blocking antibody (15), we investigated the possibility that β 7 I-tsNP retained the capacity to directly block any adhesive interaction with MAdCAM-1. Cell adhesion assays using Mn 2+ -or PMA-stimulated splenocytes showed that β 7 I-tsNP interfered with adhesive interactions to MAdCAM-1. This result may at least partly account for its mild anticolitis effect independently of cyclin D1-knockdown (i.e., β 7 I-tsNP entrapping irrelevant luciferase siRNA mildly blocked the body weight loss at day 9 in Fig. 4A ). Thus, β 7 I-tsNP might act synergistically, both through cyclin D1-knockdown and via perturbation of β 7 integrin-MAdCAM-1 interactions. To study the possibility that sNP might be sufficient for delivering CyD1-siRNA to CD44 high -activated leukocytes, and/or that the presence of hyaluronan might exert some anti-inflammatory effects ameliorating colitis, 2.5 mg/kg CyD1-siRNA entrapped in sNP, β 7 I-tsNP, or IgG-sNP were i.v. injected to mice at days 0, 2, 4, and 6 during the course of DSS-induced colitis. The severity of colitis was monitored by the change in body weight over the course of the disease (A) and by hematocrit (HCT) at day 9 (B). (A & B) Data are expressed as the mean ± SEM of 6 mice per group in two independent experiments. Note that in contrast to β 7 I-tsNP-entrapping CyD1-siRNA, sNP-entrapping CyD1-siRNA blocked neither a body weight loss nor a hematocrit reduction in DSS-induced colitis. Table S1 . Summary of nanoparticle surface modification and siRNA entrapment. 1 The number of mAbs attached to particles was determined as described in Methods using 125 I-labeled mAbs. 2 The number of siRNA entrapped in particles and 3 the entrapment efficacy were determined as described in Methods using RiboGreen TM assay. Data are expressed as the mean ± SEM of at least three independent experiments. Nanoparticle mAb 1 (molecules/particle) siRNA 2 (molecules/particle) siRNA entrapment efficacy 3 (%)
IgG sNP 45 ± 15 3750 ± 1300 78 ± 10 β 7 I-tsNP 43 ± 17 4000 ± 1200 80 ± 12 Table S2 . Diameter and Zeta potential measurements of nanoparticles before and after an entrapment or a surface-association of siRNA/protamine complexes. The siRNA entrapment protocol used in this study, which involves the addition of a protaminecondensed siRNA solution to lyophilized β 7 I-tsNP, maintained the nano-dimensions (~150 nm) of particles, and exhibited only a mild neutralization of the β 7 I-tsNP surface charge (a positive shift from ~-24 to ~-18 mV). By contrast, substantial surfaceassociation, deliberately induced by an addition of a protamine-condensed siRNA solution to water-rehydrated β 7 I-tsNP, appeared to form growing aggregates (~ 870 nm), and exhibited a considerable neutralization of the β 7 I-tsNP surface charge (a positive shift from ~-24 to ~-4 mV). All measurements were performed using a Zetasizer nano ZS instrument (Malvern) at pH 6.7, 10 mM NaCl at 20 0 C. 1 siRNAs (1 nmol) were mixed with protamine (5 nmol) in H 2 O at room temperature for 20 min in RNase-free tubes. Table S3 . Hyaluronan maintains the nano-dimensions of particles during a cycle of lyophilization and rehydration. 1 Particle size was determined using a Malvern Zetasizer nano ZS™ Zeta potential and Dynamic Light Scattering Instrument (Malvern Instruments Ltd., Southborough, MA). Data are expressed as the mean ± SEM of 6 independent measurements.
